Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Weihao Chen, Yuting Yan, Ying Yu, Yuxi Li, Xiong Wenjie, Xinyi Zhang, Tingyu Wang, Wei LIU, Weiwei Sui, Zhen Yu, Mu Hao, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2025-3593

Published: 2025

Journal Articles

Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells

Kun Jia, Xinyi Zhang, Roshani Sinha, Eric Soupene, Benjamin Lesch, Alexander Pendergast, Rachel Choi, Elisabetta Foppiani, Zachary Kostamo, Marco Cordero, Tippi MacKenzie, Vivien Sheehan, Kyle Cromer

Blood (2025) 146 (Supplement 1): 2531.

https://doi.org/10.1182/blood-2025-2531

Published: 2025

Journal Articles

Daratumumab-pomalidomide-dexamethasone (DPd) in newly diagnosed AL amyloidosis: High rates of hematologic and organ responses with manageable safety

Honglan Qian, Shuxia Zhu, Bingxin Zhang, Xinyi Zhang, Luning Cui, DONG Zheng, Huiying Mao, Mengxiong Shi, Yibo Xia, Yu Zhang, Shujuan Zhou, Songfu Jiang, Yongyong Ma

Blood (2025) 146 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2025-2188

Published: 2025

Journal Articles

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Yuting Yan, Dandan Shan, Ying Yu, Weihao Chen, Xinyi Zhang, Xiong Wenjie, Tingyu Wang, Mu Hao, Gang An, Lu-Gui Qiu, Zhen Yu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 832.

https://doi.org/10.1182/blood-2024-201941

Published: 2024

Journal Articles

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew J Weinstock, Jeffrey A Barnes, Jose Sandoval-Sus, Xianming Tan, Xinyi Zhang, Areej El-Jawahri, Shayna Sarosiek, John Mark Sloan

Blood (2021) 138 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2021-144422

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells

Daratumumab-pomalidomide-dexamethasone (DPd) in newly diagnosed AL amyloidosis: High rates of hematologic and organ responses with manageable safety

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells

Daratumumab-pomalidomide-dexamethasone (DPd) in newly diagnosed AL amyloidosis: High rates of hematologic and organ responses with manageable safety

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only